PUBLISHER: The Business Research Company | PRODUCT CODE: 1957689
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957689
Prescription orthopedic drugs are medications prescribed specifically to treat conditions impacting the musculoskeletal system, including bones, joints, muscles, and ligaments. They help relieve pain, reduce inflammation, and support healing in orthopedic injuries or disorders such as arthritis, fractures, and tendonitis.
The primary categories of prescription medications for orthopedic conditions include nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and additional types. Nonsteroidal anti-inflammatory drugs (NSAIDs) form a group of medicines that alleviate pain, swelling, and fever by blocking enzymes responsible for prostaglandin synthesis. Providers prescribe them for issues like osteoarthritis, rheumatoid arthritis, osteoporosis, and similar conditions. These medications reach patients via multiple outlets, such as hospital pharmacies, retail pharmacies, and online pharmacies.
Tariffs have increased the cost of imported APIs used in NSAIDs, corticosteroids, and biologics that are commonly prescribed for orthopedic conditions. These impacts are most evident in North America and Europe, where reliance on cross border sourcing has intensified pricing pressure. Rising tariff related expenses have influenced treatment affordability, reimbursement discussions, and procurement planning in orthopedic care. This has affected purchasing decisions across hospitals and specialty clinics. Positively, tariffs are encouraging domestic orthopedic drug production, expanded local manufacturing capacity, and stronger regional pharmaceutical supply chains over the long term.
The prescription orthopedic drugs market research report is one of a series of new reports from The Business Research Company that provides prescription orthopedic drugs market statistics, including prescription orthopedic drugs industry global market size, regional shares, competitors with a prescription orthopedic drugs market share, detailed prescription orthopedic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prescription orthopedic drugs industry. This prescription orthopedic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The prescription orthopedic drugs market size has grown strongly in recent years. It will grow from $51.06 billion in 2025 to $54.01 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to high prevalence of arthritis, increased orthopedic surgeries, widespread NSAID use, aging population joint disorders, expansion of orthopedic healthcare facilities.
The prescription orthopedic drugs market size is expected to see strong growth in the next few years. It will grow to $67.5 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rising osteoarthritis cases, growing demand for long-term pain control, expansion of biologic orthopedic drugs, increased sports injury incidence, rising orthopedic drug prescriptions. Major trends in the forecast period include rising demand for pain management therapies, increased use of anti-inflammatory orthopedic drugs, growing focus on chronic joint disorder treatment, expansion of dmard usage in orthopedics, increased adoption of combination pain therapies.
The rising prevalence of musculoskeletal disorders is projected to fuel the expansion of the prescription orthopedic drugs market in the future. Musculoskeletal disorders (MSDs) refer to injuries and conditions impacting the human body's musculoskeletal system-which encompasses muscles, tendons, ligaments, nerves, and joints-leading to pain and impaired mobility. This uptick in MSDs stems mainly from factors like aging populations, work-related repetitive motions and poor postures, sedentary lifestyles coupled with unhealthy diets, and hereditary factors. Prescription orthopedic drugs are essential for treating these disorders, as they relieve pain, curb inflammation, and support recovery, ultimately boosting mobility and quality of life. For example, in March 2023, data from the UK's Office for Health Improvement & Disparities showed that the rate of long-term self-reported musculoskeletal (MSK) conditions among those aged 16 and older climbed to 17.6% in 2022. Thus, the growing incidence of musculoskeletal disorders is propelling the prescription orthopedic drugs market forward.
Major companies in the prescription orthopedic drugs market are prioritizing the expansion of indications for their drugs to widen their scope, such as developing extended-indication analgesic formulations to improve postoperative pain management for a wider array of orthopedic and soft-tissue procedures. An extended-indication analgesic formulation is a pain-relief medication whose approved clinical applications have been extended to include more medical procedures, conditions, or patient populations beyond its initial approval. For example, in January 2023, Heron Therapeutics Inc., a US-based biotechnology firm, secured FDA approval for the broadened use of ZYNRELEF (bupivacaine and meloxicam) in soft tissue and orthopedic procedures, including foot and ankle surgeries. This extended-release formulation is specially engineered to deliver sustained pain relief for up to 72 hours, often reducing or eliminating the need for post-surgical opioids. The expanded indication now encompasses more orthopedic and soft tissue procedures, including foot and ankle surgeries, increasing its utility in clinical practice. Its novel dual-drug approach combines local anesthetic and anti-inflammatory properties, offering a complete solution for postoperative pain control with better patient results.
In April 2024, ProMed Pharma LLC, a U.S.-based pharmaceutical firm, purchased SpineThera Inc. for an undisclosed sum. Through this acquisition, ProMed seeks to bolster its drug delivery expertise by tapping into SpineThera's proficiency in extended-release injectable treatments, especially for pain relief in musculoskeletal and orthopedic issues.
Major companies operating in the prescription orthopedic drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck KGaA, AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., UCB S.A., Allergan plc, Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd.
North America was the largest region in the prescription orthopedic drugs market in 2025. The regions covered in the prescription orthopedic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the prescription orthopedic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The prescription orthopedic drugs market consists of sales of products such as bisphosphonates, creams, gels, or patches, calcium and vitamin D supplements, and analgesics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Prescription Orthopedic Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses prescription orthopedic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for prescription orthopedic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The prescription orthopedic drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.